Saquinavir: major study shows survival benefit in treatment-naive patients.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Saquinavir: major study shows survival benefit in treatment-naive patients.

AIDS Treat News. 1997 Jul 4;(No 274):6. Unique Identifier : AIDSLINE MED/97702752
James JS; Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD; 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Abstract: The largest trial ever on AIDS treatment (3,400 volunteers with little or no prior antiviral treatment) reveals that triple drug treatment using saquinavir plus zidovudine (AZT) plus zalcitabine ddC) reduced disease progression or death by fifty percent, compared to AZT plus ddC. Deaths alone were reduced by about 42 percent; however, the result was not quite statistically significant due to the small number of deaths. Those entering the trial had a median CD4 count of approximately 200 and a median viral load of 100,000. Median treatment was 14 months, and median time of follow-up for clinical endpoints was 17 months.

Keywords: *Anti-HIV Agents/THERAPEUTIC USE *HIV Infections/DRUG THERAPY *HIV Protease Inhibitors/THERAPEUTIC USE *Saquinavir/THERAPEUTIC USE
971230
M97C1571

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .